S8633
Sphingomyelinase from Staphylococcus aureus
buffered aqueous glycerol solution, 100-300 units/mg protein (Lowry)
Synonym(s):
Sphingomyelin choline phosphohydrolase, Sphingomyelin phosphodiesterase
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
CAS Number:
UNSPSC Code:
12352204
NACRES:
NA.32
MDL number:
Specific activity:
100-300 units/mg protein (Lowry)
form
buffered aqueous glycerol solution
Quality Level
specific activity
100-300 units/mg protein (Lowry)
storage temp.
2-8°C
Application
Sphingomyelinase from Staphylococcus aureus has been used to:
- induce neurotoxicity in rat cortical cultures to study the protective effects of minocycline
- determine the concentration of sphingomyelin from serum samples
- enhance sphingomyelinase activity to study PARK9-mediated exosome biogenesis
Biochem/physiol Actions
Bacterial sphingomyelinase is active at neutral pH. When used in cell culture in vitro, it hydrolyzes the sphingomyelin on the outer leaflet of the plasma membrane and produces ceramide that is lipid-soluble. Sphingomyelinase is the key enzyme in the sphingomyelinase/ceramide pathway, which is implicated in the pathogenesis of several neurodegenerative disorders.
Initiates the formation of sphingomyelin-based second messengers. Activates MAPK (mitogen-activated protein kinase) and SAPKs (stress-activated protein kinases); generates ceramide from sphingomyelin.
Physical form
Solution in 50% glycerol containing 0.25 M phosphate buffer, pH 7.5
Other Notes
One unit will hydrolyze 1.0 μmol of TNPAL-sphingomyelin per min at pH 7.4 at 37 °C.
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Taiji Tsunemi et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(46), 15281-15287 (2014-11-14)
Kufor-Rakeb syndrome (KRS) is caused by loss-of-function mutations in ATP13A2 (PARK9) and characterized by juvenile-onset parkinsonism, pyramidal signs, and cognitive decline. Previous studies suggested that PARK9 deficiency causes lysosomal dysfunction and α-synuclein (α-syn) accumulation, whereas PARK9 overexpression suppresses toxicity of
Measurement of sphingomyelin and ceramide cellular levels after sphingomyelinase-mediated sphingomyelin hydrolysis.
P Santana et al.
Methods in molecular biology (Clifton, N.J.), 105, 217-221 (1999-07-31)
Elin Rebecka Carlsson et al.
Frontiers in endocrinology, 9, 172-172 (2018-06-21)
Metabolic surgery is superior to lifestyle intervention in reducing weight and lowering glycemia and recently suggested as treatment for type 2 diabetes mellitus. Especially Roux-en-Y gastric bypass (RYGB) has been focus for much research, but still the mechanisms of action